US FDA Approves Expanded Age Indication for GSK’s AREXVY, the First Respiratory Syncytial Virus (RSV) Vaccine for Adults Aged 50-59 at Increased Risk
Business Wire
PHILADELPHIA--(BUSINESS WIRE)-- #Adult--US FDA approves expanded age indication for GSK’s AREXVY, the first respiratory syncytial..